S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
NASDAQ:VBIV

VBI Vaccines (VBIV) Stock Price, News & Analysis

$0.63
+0.00 (+0.64%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$0.61
$0.65
50-Day Range
$0.56
$0.92
52-Week Range
$0.45
$3.53
Volume
163,500 shs
Average Volume
383,000 shs
Market Capitalization
$18.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VBI Vaccines MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
-0.32mentions of VBI Vaccines in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to ($0.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

732nd out of 908 stocks

Pharmaceutical Preparations Industry

332nd out of 414 stocks

VBIV stock logo

About VBI Vaccines Stock (NASDAQ:VBIV)

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

VBIV Stock Price History

VBIV Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
VBI Vaccines Inc. (VBIV)
Brii Biosciences To Buy VBI's IP Rights In BRII-179
VBI Vaccines Reports Third Quarter 2023 Financial Results
See More Headlines
Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2023
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VBIV
Fax
N/A
Employees
190
Year Founded
2001

Profitability

Net Income
$-113,300,000.00
Net Margins
-1,403.15%
Pretax Margin
-1,403.15%

Debt

Sales & Book Value

Annual Sales
$8.68 million
Book Value
$7.46 per share

Miscellaneous

Free Float
25,489,000
Market Cap
$18.02 million
Optionable
Optionable
Beta
1.93

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jeffery R. Baxter FCMA (Age 63)
    President, CEO & Director
    Comp: $908.06k
  • Dr. David Evander Anderson (Age 54)
    Chief Scientific Officer
    Comp: $534.25k
  • Dr. Francisco Diaz-Mitoma FRCPC (Age 69)
    M.D., Ph.D., Chief Medical Officer
    Comp: $544.52k
  • Ms. Nell BeattieMs. Nell Beattie (Age 36)
    CFO, Head of Corporate Development & Director
  • Nicole Anderson
    Director of Corporate Communications & Investor Relations
  • Ms. Athena Kartsaklis (Age 59)
    Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer
  • Mr. Avi Mazaltov (Age 62)
    Global Head of Manufacturing & GM of SciVac
  • Mr. Misha Nossov
    Senior VP of Global Commercial Supply Strategy & Head of Europe
  • Mr. T. Adam Buckley (Age 48)
    Senior Vice President of Business Development
  • Mr. John Robert Dillman (Age 56)
    Chief Commercial Officer

VBIV Stock Analysis - Frequently Asked Questions

How have VBIV shares performed in 2024?

VBI Vaccines' stock was trading at $0.5875 on January 1st, 2024. Since then, VBIV stock has increased by 7.9% and is now trading at $0.6337.
View the best growth stocks for 2024 here
.

When is VBI Vaccines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VBIV earnings forecast
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) issued its quarterly earnings data on Monday, March, 13th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.98 million. VBI Vaccines had a negative net margin of 1,403.15% and a negative trailing twelve-month return on equity of 199.61%.

When did VBI Vaccines' stock split?

Shares of VBI Vaccines reverse split on the morning of Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

How do I buy shares of VBI Vaccines?

Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VBIV) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners